Three-statement Excel model · 14 quarters and 3 fiscal years of history · 10 quarters and 5 fiscal years of projections
About the NVS model
This three-statement Excel model covers Novartis AG (NVS): its income statement, balance sheet and cash flow statement. It holds 14 quarters and 3 fiscal years of history and 10 quarters and 5 fiscal years of projections.
Projected revenue is built from KPI drivers: Net sales built brand by brand: 28 disclosed brands on their own sequential growth rates, summing to five therapeutic areas, plus one explicit line for pipeline assets not yet launched, across 5 segments.
Beyond the income statement, the workbook has these sections: KPI Drivers, Balance Sheet, Cash Flow Statement, Core (non-IFRS) Reconciliation and Net Sales by Region (memo).
Model thesis: Entresto's US cliff against six ramping launches: FY2026E net sales +3.0% on guidance, +5.05% CAGR to 2030 at the bottom of management's band, and the out-years rest on one visible pipeline line
On October 19, 2026, the model passed checks C13 (every subtotal reconciles to the reported figure at $0), C14 (every projected revenue cell traces to a KPI driver row) and C15 (each driver ends in a rate, a count or a historical anchor, never a typed-in projected dollar level). It was last updated September 28, 2026.
Income statement preview
Columns FY2023–FY2025 are actual results and FY2026E–FY2028E are our estimates. Figures were recalculated in Excel on September 28, 2026. USD in millions, except per share.
| Income Statement | ||||||
|---|---|---|---|---|---|---|
| Actual | Estimate | |||||
| FY2023 | FY2024 | FY2025 | FY2026E | FY2027E | FY2028E | |
| Net Sales - Cardiovascular, Renal and Metabolic | $6,390 | $8,576 | $8,959 | $6,679 | $6,731 | $6,954 |
| Net Sales - Immunology | 7,798 | 9,293 | 10,293 | 10,747 | 11,101 | 11,361 |
| Net Sales - Neuroscience | 3,651 | 4,750 | 5,993 | 7,247 | 8,131 | 8,843 |
| Net Sales - Oncology | 12,851 | 14,297 | 16,830 | 17,865 | 20,631 | 22,564 |
| Net Sales - Established Brands | 14,750 | 13,401 | 12,457 | 13,621 | 12,978 | 12,456 |
| Net Sales - Pipeline Assets Not Yet Launched | 0 | 0 | 0 | 0 | 302 | 1,254 |
| Total Net Sales | $45,440 | $50,317 | $54,532 | $56,159 | $59,874 | $63,433 |
| Other Revenues | $1,220 | $1,405 | $2,142 | $1,971 | $2,096 | $2,157 |
| Total Revenue | $46,660 | $51,722 | $56,674 | $58,130 | $61,969 | $65,590 |
| Less: Cost of Goods Sold | ($12,472) | ($12,827) | ($13,699) | ($15,028) | ($16,236) | ($16,922) |
| Gross Profit | $34,188 | $38,895 | $42,975 | $43,102 | $45,733 | $48,667 |
| Less: Selling, General and Administration | ($12,517) | ($12,566) | ($13,248) | ($13,558) | ($14,749) | ($15,348) |
| Less: Research and Development | (11,371) | (10,022) | (11,200) | (11,978) | (13,014) | (13,511) |
| Other Income | 1,772 | 1,175 | 1,460 | 1,748 | 1,797 | 1,902 |
| Less: Other Expense | (2,303) | (2,938) | (2,343) | (2,279) | (2,107) | (2,164) |
| Total Operating Expenses and Other, net | ($24,419) | ($24,351) | ($25,331) | ($26,068) | ($28,072) | ($29,122) |
| Operating Income | $9,769 | $14,544 | $17,644 | $17,034 | $17,661 | $19,546 |
| Add: Depreciation, Amortisation and Impairments | $8,277 | $6,069 | $5,325 | $5,532 | $5,633 | $5,440 |
| EBITDA | $18,046 | $20,613 | $22,969 | $22,566 | $23,294 | $24,986 |
| Loss from Associated Companies | ($13) | ($38) | ($12) | ($11) | ($12) | ($12) |
| Less: Interest Expense | (855) | (1,006) | (1,144) | (1,735) | (1,860) | (1,860) |
| Other Financial Income and Expense | 222 | 140 | (136) | (117) | (100) | (100) |
| Income Before Taxes | $9,123 | $13,640 | $16,352 | $15,171 | $15,689 | $17,574 |
| Less: Income Taxes | (551) | (1,701) | (2,385) | (2,860) | (2,589) | (2,900) |
| Net Income from Continuing Operations | $8,572 | $11,939 | $13,967 | $12,311 | $13,100 | $14,674 |
| Net Income from Discontinued Operations (Sandoz) | $6,282 | $0 | $0 | $0 | ||
| of which: Sandoz result before the distribution gain | 422 | 0 | 0 | 0 | ||
| of which: gain on distribution of Sandoz Group AG | 5,860 | 0 | 0 | 0 | ||
| Net Income | $14,854 | $11,939 | $13,967 | $12,311 | $13,100 | $14,674 |
| Attributable to Shareholders of Novartis AG | $14,850 | $11,941 | $13,984 | $12,326 | $13,116 | $14,690 |
| Attributable to Non-Controlling Interests | 4 | (2) | (17) | (15) | (16) | (16) |
| Net Income, Attributed | $14,854 | $11,939 | $13,967 | $12,311 | $13,100 | $14,674 |
| Weighted Average Shares Outstanding - Basic (million) | 2,077 | 2,018 | 1,939 | 1,901 | 1,878 | 1,857 |
| Weighted Average Shares Outstanding - Diluted (million) | 2,092 | 2,035 | 1,955 | 1,913 | 1,893 | 1,873 |
| Basic Earnings per Share | $7.15 | $5.92 | $7.21 | $6.48 | $6.99 | $7.91 |
| Diluted Earnings per Share | $7.10 | $5.87 | $7.15 | $6.44 | $6.93 | $7.84 |
| Ratios & Assumptions | ||||||
| YoY Total Net Sales Growth | 10.7% | 8.4% | 3.0% | 6.6% | 5.9% | |
| Gross Margin | 75.2% | 77.3% | 78.8% | 76.7% | 76.4% | 76.7% |
| Operating Margin | 21.5% | 28.9% | 32.4% | 30.3% | 29.5% | 30.8% |
| Net Margin | 32.7% | 23.7% | 25.6% | 21.9% | 21.9% | 23.1% |
| Effective Tax Rate | 6.0% | 12.5% | 14.6% | 18.9% | 16.5% | 16.5% |
The full workbook adds 14 historical and 10 projected quarters, plus KPI Drivers · Balance Sheet · Cash Flow Statement · Core (non-IFRS) Reconciliation · Net Sales by Region (memo) — every subtotal a live formula, every projection traced to a driver.
Novartis research
Aardvark Labs Capital Research has published 5 reports on Novartis (NVS). The latest is the Q3 2026 Earnings Recap, published October 31, 2026, rated Hold.
Novartis Raises Its Profit Guide in the Quarter Two of Its Three Big Bets Failed
Methodology
Every projected revenue cell traces to a KPI/driver row (C14). Terminal driver cells are rates, counts, or historical anchors — never typed-in projected dollar levels (C15). Every subtotal-vs-reported reconciliation row ties to $0 (C13). Each model is written per-ticker against its actual schema — no cloning, no level-input shortcuts.